Stockscreener 앱 받기
21.11
3.15%
0.645
시간 외 거래:
21.07
-0.035
-0.17%
전일 마감가:
$20.46
열려 있는:
$20.71
하루 거래량:
305.61K
Relative Volume:
0.46
시가총액:
$881.19M
수익:
$5.92M
순이익/손실:
$-75.79M
주가수익비율:
-9.983
EPS:
-2.1141
순현금흐름:
$-59.15M
1주 성능:
-4.67%
1개월 성능:
+4.74%
6개월 성능:
+348.09%
1년 성능:
+372.15%
1일 변동 폭
$20.27
$21.35
1주일 범위
$20.00
$22.59
52주 변동 폭
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
명칭
Bioage Labs Inc
전화
510-806-1445
주소
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
21.11 | 854.26M | 5.92M | -75.79M | -59.15M | -2.1141 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2026-01-27 | 개시 | Piper Sandler | Overweight |
| 2025-12-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2024-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-21 | 개시 | Citigroup | Buy |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-21 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
Market Trends: How does BioAge Labs Inc perform in inflationary periodsTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn
BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit - Law360
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 7,433 shares in 10b5-1 trade - Stock Titan
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs (NASDAQ:BIOA) Shares Gap DownHere's Why - MarketBeat
Risk Analysis: How does BioAge Labs Inc perform in inflationary periods2025 Performance Recap & Community Driven Trade Alerts - baoquankhu1.vn
Investment Recap: How do insiders feel about BioAge Labs Inc2025 Geopolitical Influence & Weekly High Return Stock Opportunities - baoquankhu1.vn
BIOA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion - Yahoo Finance
Oppenheimer Begins Coverage on BioAge Labs (NASDAQ:BIOA) - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Oppenheimer Initiates Coverage of BioAge Labs (BIOA) with Outperform Recommendation - Nasdaq
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal - TipRanks
BioAge Labs (BIOA) Price Target Increased by 10.09% to 30.60 - Nasdaq
Oppenheimer initiates BioAge Labs stock coverage with outperform rating By Investing.com - Investing.com Canada
Oppenheimer initiates BioAge Labs stock coverage with outperform rating - Investing.com
Technical Analysis: Is BioAge Labs Inc backed by strong institutional buyingQuarterly Portfolio Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Fed Watch: Whats the beta of BioAge Labs Inc stock2025 Market Sentiment & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
BioAge Labs, Inc. (BIOA) Receives Buy Rating From Jefferies With Significant Upside Potential - 富途牛牛
BioAge Labs (BIOA) CEO Kristen Fortney awarded 330,000 stock options - Stock Titan
Jefferies upgrades BioAge Labs stock rating on drug potential By Investing.com - Investing.com Nigeria
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Jefferies Upgrades BioAge Labs (BIOA) - Nasdaq
Jefferies upgrades BioAge Labs stock rating on drug potential - Investing.com
Should You Buy BIOAGE Labs Inc (BIOA) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Down 16.3% in January - MarketBeat
Is BioAge Labs Inc.’s ROE strong enough2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - mfd.ru
Will BioAge Labs Inc. stock hit new highs in YEARQuarterly Portfolio Review & AI Forecasted Stock Moves - mfd.ru
Will BioAge Labs Inc. stock deliver long term returnsWatch List & Weekly Breakout Watchlists - mfd.ru
How BioAge Labs Inc. stock benefits from tech adoptionEarnings Trend Report & Real-Time Volume Triggers - mfd.ru
Whale Trades: What is Columbia Sportswear Companys P E ratio telling usJuly 2025 Analyst Calls & Expert-Curated Trade Recommendations - baoquankhu1.vn
Returns Recap: Is BioAge Labs Inc a good stock for dollar cost averagingJuly 2025 Technicals & Consistent Profit Trade Alerts - baoquankhu1.vn
Can BioAge Labs Inc. lead its sector in growthJuly 2025 Weekly Recap & Expert Verified Stock Movement Alerts - mfd.ru
BioAge Labs (NASDAQ:BIOA) Trading Down 5.6%Here's What Happened - MarketBeat
Can BioAge Labs Inc. stock hit analyst price targetsWeekly Trade Analysis & High Accuracy Swing Trade Signals - mfd.ru
S P Trends: Whats the beta of BioAge Labs Inc stockShare Buyback & Consistent Return Investment Signals - baoquankhu1.vn
BioAge Labs (BIOA) Price Target Increased by 127.08% to 27.80 - Nasdaq
Morgan Stanley Boosts Price Target on BioAge Labs to $23 From $12, Keeps Equalweight Rating - marketscreener.com
BioAge Labs (NASDAQ:BIOA) Insider Sells $139,368.75 in Stock - MarketBeat
BioAge Labs (NASDAQ:BIOA) Upgraded at Wall Street Zen - MarketBeat
BioAge Labs (NASDAQ:BIOA) Trading 8% HigherHere's Why - MarketBeat
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential - Pharma Voice
BioAge Labs Completes $115 Million Upsized Public Offering - Global Legal Chronicle
Piper Sandler Initiates Coverage of BioAge Labs (BIOA) with Overweight Recommendation - Nasdaq
BioAge Labs (NASDAQ:BIOA) Shares Gap UpShould You Buy? - MarketBeat
Piper Sandler Initiates BioAge Labs at Overweight With $73 Price Target - marketscreener.com
BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating - TipRanks
BioAge Labs stock initiated with Overweight rating by Piper Sandler - Investing.com UK
Bioage Labs Inc (BIOA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bioage Labs Inc 주식 (BIOA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Mar 02 '26 |
Sale |
20.30 |
7,433 |
150,890 |
0 |
| GOLDSTEIN DOV A MD | Chief Financial Officer |
Mar 01 '26 |
Option Exercise |
4.38 |
3,542 |
15,514 |
33,033 |
0.21%
1.77%
자본화:
|
볼륨(24시간):